GENOWAY SA (ALGEN.PA) Fundamental Analysis & Valuation

EPA:ALGEN • FR0004053510

Current stock price

2.49 EUR
-0.03 (-1.19%)
Last:

This ALGEN.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. ALGEN.PA Profitability Analysis

1.1 Basic Checks

  • In the past year ALGEN was profitable.
  • ALGEN had a negative operating cash flow in the past year.
  • In multiple years ALGEN reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.
ALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFALGEN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M

1.2 Ratios

  • ALGEN has a better Return On Assets (3.31%) than 77.50% of its industry peers.
  • The Return On Equity of ALGEN (7.00%) is better than 78.75% of its industry peers.
  • With a decent Return On Invested Capital value of 3.17%, ALGEN is doing good in the industry, outperforming 73.75% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for ALGEN is significantly below the industry average of 11.89%.
Industry RankSector Rank
ROA 3.31%
ROE 7%
ROIC 3.17%
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ALGEN.PA Yearly ROA, ROE, ROICALGEN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • With a decent Profit Margin value of 6.14%, ALGEN is doing good in the industry, outperforming 75.00% of the companies in the same industry.
  • ALGEN's Operating Margin of 5.97% is fine compared to the rest of the industry. ALGEN outperforms 73.75% of its industry peers.
  • ALGEN has a Gross Margin of 94.91%. This is amongst the best in the industry. ALGEN outperforms 87.50% of its industry peers.
  • In the last couple of years the Gross Margin of ALGEN has remained more or less at the same level.
Industry RankSector Rank
OM 5.97%
PM (TTM) 6.14%
GM 94.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
ALGEN.PA Yearly Profit, Operating, Gross MarginsALGEN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ALGEN.PA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALGEN is destroying value.
  • ALGEN has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ALGEN has more shares outstanding
  • The debt/assets ratio for ALGEN has been reduced compared to a year ago.
ALGEN.PA Yearly Shares OutstandingALGEN.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALGEN.PA Yearly Total Debt VS Total AssetsALGEN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • An Altman-Z score of 1.99 indicates that ALGEN is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • ALGEN has a better Altman-Z score (1.99) than 62.50% of its industry peers.
  • ALGEN has a Debt/Equity ratio of 0.71. This is a neutral value indicating ALGEN is somewhat dependend on debt financing.
  • ALGEN has a Debt to Equity ratio of 0.71. This is comparable to the rest of the industry: ALGEN outperforms 53.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Altman-Z 1.99
ROIC/WACC0.43
WACC7.36%
ALGEN.PA Yearly LT Debt VS Equity VS FCFALGEN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

2.3 Liquidity

  • A Current Ratio of 2.41 indicates that ALGEN has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.41, ALGEN perfoms like the industry average, outperforming 52.50% of the companies in the same industry.
  • A Quick Ratio of 2.21 indicates that ALGEN has no problem at all paying its short term obligations.
  • The Quick ratio of ALGEN (2.21) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.41
Quick Ratio 2.21
ALGEN.PA Yearly Current Assets VS Current LiabilitesALGEN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ALGEN.PA Growth Analysis

3.1 Past

  • ALGEN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.46%.
  • ALGEN shows a decrease in Revenue. In the last year, the revenue decreased by -2.21%.
  • The Revenue has been growing by 18.46% on average over the past years. This is quite good.
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%

3.2 Future

  • Based on estimates for the next years, ALGEN will show a decrease in Earnings Per Share. The EPS will decrease by 0.00% on average per year.
  • ALGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.17% yearly.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-11.76%
Revenue Next 2Y0.63%
Revenue Next 3Y11.17%
Revenue Next 5YN/A

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALGEN.PA Yearly Revenue VS EstimatesALGEN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
ALGEN.PA Yearly EPS VS EstimatesALGEN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2023 2024 2027 0.05 0.1 0.15 0.2

More info and screens

Find the best growth stocksShow best growing peers

2

4. ALGEN.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 16.60, ALGEN is valued correctly.
  • Based on the Price/Earnings ratio, ALGEN is valued cheaply inside the industry as 90.00% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 25.60. ALGEN is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 16.6
Fwd PE N/A
ALGEN.PA Price Earnings VS Forward Price EarningsALGEN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • 90.00% of the companies in the same industry are more expensive than ALGEN, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.17
ALGEN.PA Per share dataALGEN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALGEN.PA Dividend Analysis

5.1 Amount

  • ALGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALGEN.PA Fundamentals: All Metrics, Ratios and Statistics

GENOWAY SA

EPA:ALGEN (4/2/2026, 7:00:00 PM)

2.49

-0.03 (-1.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners7.76%
Ins Owner ChangeN/A
Market Cap31.62M
Revenue(TTM)20.95M
Net Income(TTM)1.29M
Analysts86.67
Price Target4.49 (80.32%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-25.42%
PT rev (3m)-25.42%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-4.98%
Revenue NY rev (3m)-4.98%
Valuation
Industry RankSector Rank
PE 16.6
Fwd PE N/A
P/S 1.51
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB 2.55
EV/EBITDA 10.17
EPS(TTM)0.15
EY6.02%
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS1.65
BVpS1.45
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.21
Profitability
Industry RankSector Rank
ROA 3.31%
ROE 7%
ROCE 3.94%
ROIC 3.17%
ROICexc 3.17%
ROICexgc 3.91%
OM 5.97%
PM (TTM) 6.14%
GM 94.91%
FCFM N/A
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Debt/EBITDA 2.88
Cap/Depr 297.91%
Cap/Sales 46.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.41
Quick Ratio 2.21
Altman-Z 1.99
F-Score3
WACC7.36%
ROIC/WACC0.43
Cap/Depr(3y)64.02%
Cap/Depr(5y)125.45%
Cap/Sales(3y)10.32%
Cap/Sales(5y)17.64%
Profit Quality(3y)100.54%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%
Revenue Next Year-11.76%
Revenue Next 2Y0.63%
Revenue Next 3Y11.17%
Revenue Next 5YN/A
EBIT growth 1Y-28.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year190%
EBIT Next 3Y73.25%
EBIT Next 5YN/A
FCF growth 1Y-380.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.89%
OCF growth 3YN/A
OCF growth 5YN/A

GENOWAY SA / ALGEN.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for GENOWAY SA?

ChartMill assigns a fundamental rating of 4 / 10 to ALGEN.PA.


What is the valuation status of GENOWAY SA (ALGEN.PA) stock?

ChartMill assigns a valuation rating of 2 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Overvalued.


Can you provide the profitability details for GENOWAY SA?

GENOWAY SA (ALGEN.PA) has a profitability rating of 4 / 10.


How financially healthy is GENOWAY SA?

The financial health rating of GENOWAY SA (ALGEN.PA) is 5 / 10.


What is the expected EPS growth for GENOWAY SA (ALGEN.PA) stock?

The Earnings per Share (EPS) of GENOWAY SA (ALGEN.PA) is expected to decline by -100% in the next year.